News

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

As the coronavirus pandemic unfolds, Pharma must practice science over hype.

Specialty pharmaceutical company, Diurnal, has announced that the marketing authorization application (MAA) for Chronocort has passed validation with the European Medicines Agency (EMA).

N4 Pharma will be undertaking a proof-of-concept research project using a COVID-19 DNA plasmid to demonstrate the ability of its delivery system, Nuvec, to collaborative partners developing DNA or RNA vaccines.

Regulatory emergency planning has been put to the test with the COVID-19 pandemic.

As COVID-19 rapidly spreads, the bio/pharma industry is committing significant efforts to fast track development of therapies.

CPS will be integrated into CB, who will proceed as the operating company while CMIC group continues to expand its business in China.

The companies are entering into a partnership to develop fully human neutralizing antibodies targeting SARS-CoV-2 to prevent or treat COVID-19.

The event, which was originally scheduled for May 11–13, 2020 at the Gaylord Palms Resort and Convention Center in Kissimmee, FL, will be canceled due to concerns regarding the spread of COVID-19.

GE biopharma brands are now part of Cytiva, a Danaher Corporation Life Sciences company.

With new tests showing NDMA levels increase under normal storage conditions, FDA calls for removal of ranitidine products from the market.

Daiichi Sankyo has entered into a partnership with Ultragenyx Pharmaceutical for the use of Ultragenyx’s proprietary AAV-based gene-therapy manufacturing technology.

The patent includes the use of fibroblast cells and adjuvants such as peptides and hydroxychloroquine, which fuels the assembly of natural interferon to overpower the virus.

The new patented process results in uniform, scalable production and the ability to deliver cell cargo similar to natural exosomes/extracellular vesicles.

The company is currently seeking interest from companies who have the skill and means to rapidly advance BOLD-100 for the treatment of COVID-19.

The partnership will focus on the development of up to five novel protein replacement and mRNA therapies.

S is now permitted to import human blood/blood products, other bodily fluids, and tissues that may contain novel coronavirus into its Newark, DE, facility.

The measurement device comes with an infrared semiconductor to examine the molecular structure of materials in a wavelength range up to 2,5 µm for factory and lab applications.

The system, which works to miniaturize, integrate, and automate bioanalytical processes, will give JIB students enrolled in the school’s specialist graduate, PhD, and industry training programs the ability to enhance their industry skills via access to Gyrolab systems and ready-to-use kits.

The Lanexo Lab Inventory, Safety, and Compliance Management System is a digital laboratory informatics solution formulated to reduce time in labs and improve data quality and traceability.

Pre-clinical immunization studies of iBio’s SARS-CoV-2 VLP candidates are being performed by Texas A&M.

The bill includes multiple less-noticed provisions to bolster healthcare programs and to advance the development of new treatments and preventives to combat the virus.

Johnson & Johnson announces clinical trial plans for COVID-19 vaccine candidate, as well as plans to produce 1 billion vaccine doses.

The joint public-private initiative will provide $4 million in funding to a Johns Hopkins-led research team exploring therapeutic uses of blood plasma from recovered COVID-19 patients.

AzarGen’s biosimilar, made in iBio’s plant-based system, will be compared to the original molecule in pre-clinical studies.

ProBioGen will facilitate the development of Immunogenesis’ monoclonal antibody candidate and will be responsible for manufacturing the drug at its new facility in Berlin, Germany.

The companies will use CytomX’s Probody therapeutic technology platform and its proprietary bispecific formats and CD3 modules.

The company is developing the first humanized antibody that can control the inflammatory response and prevent uncontrolled inflammation connected to the virus.

Data and analytics company GlobalData announced that there is a strain on the global biopharma industry’s supply chain due to the ongoing outbreak of COVID-19.

Prior to the global market downturn, data from the United Kingdom BioIndustry Association (BIA) and Informa Pharma Intelligence have revealed that biotech companies in the UK had raised £309 million (US$379 million).